Effect of Peritoneal Dialysis Solution Type on Serum Lipid Levels in End-Stage Renal Disease

REFERENCES

• Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int. 1999; 19: 35–43
   Google Scholar
• Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipoprotein (a) in patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1993; 8: 609–613
   PubMed Web of Science ®Google Scholar
• Brunner FP, Fassbinder W, Broyer M, et al. Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial Transplant. 1988; 3: 109–122
   PubMedGoogle Scholar
• Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extend of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000; 35: 352–362
   Web of Science ®Google Scholar
• Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis. 1996; 28: 910–917
   PubMed Web of Science ®Google Scholar
• Bagdade JD, Porte D, Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med. 1968; 279: 181–185
   PubMed Web of Science ®Google Scholar
• Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998; 105: 48–57
   PubMedGoogle Scholar
• Steele J, Billington T, Janus E, Moran J. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis. 1989; 79: 47–50
   PubMed Web of Science ®Google Scholar
• Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int. 1998; 18: 505–511
   PubMed Web of Science ®Google Scholar
• Pers E. Icodextrin plus glucose combinations for use in CAPD. Perit Dial Int. 1997; 17: 68–69
   Web of Science ®Google Scholar
• Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 1994; 46: 496–503
   PubMed Web of Science ®Google Scholar
• Oreopoulos DG, Crassweller P, Katirtzoglu A, . Amino acids as an osmotic agent (instead of glucose) in continuous ambulatory peritoneal dialysis. Proceedings of an International Symposium. Amsterdam: Excerpta Medica, M Legrain, et al. 1979; 335–340
   Google Scholar
• Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand. 1986; 220: 143–151
   PubMed Web of Science ®Google Scholar
• Lindholm B, Bergstrouml MJ. Nutritional aspects of CAPD. Continuous ambulatory peritoneal dialysis, R Gokal. Churchill-Livingstone, London 1986; 228–265
   Google Scholar
• Young EA, Drummond A, Cool DA, et al. The effect of insulin on the metabolism of parenteral maltose in man. J Clin Endocrinol Metab. 1980; 50: 764–772
   PubMed Web of Science ®Google Scholar
• Posthuma N, Ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CAPD patients. Perit Dial Int. 1999; 19: 334–342
   PubMed Web of Science ®Google Scholar
• Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R, et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001; 21: 275–281
   PubMed Web of Science ®Google Scholar
• Young GA, Dibble JB, Hobson SM, et al. The use of an amino-acid-based CAPD fluid over 12 weeks. Nephrol Dial Transplant. 1989; 4: 285–292
   PubMed Web of Science ®Google Scholar
• Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid dialysis solution: a long term, cross-over study. Kidney Int. 1989; 35: 1189–1194
   PubMed Web of Science ®Google Scholar
• Pedersen FB. Alternate use of amino acid and glucose solutions in CAPD. A review. Contrib Nephrol. 1991; 89: 147–154
   PubMedGoogle Scholar
• Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997; 17: 279–286
   PubMed Web of Science ®Google Scholar
• Dibble JB, Young GA, Hobson SM, Brownjohn AM. Amino-acid-based continuous ambulatory peritoneal dialysis (CAPD) fluid over twelve weeks: effects on carbohydrate and lipid metabolism. Perit Dial Int. 1990; 10: 71–77
   PubMed Web of Science ®Google Scholar
• Oren A, Wu G, Anderson GH, et al. Effective use of amino acid dialysate over four weeks in CAPD patients. Trans Am Soc Artif Intern Organs. 1983; 29: 604–610
   PubMedGoogle Scholar
• Dombros NV, Prutis K, Tong M, et al. Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients—no effect on nutritional status. Perit Dial Int. 1990; 10: 79–84
   PubMed Web of Science ®Google Scholar
• Renzo S, Beatrice D, Guiseppe L. CAPD in diabetics: use of amino acids. Advances in CAPD, R Khanna, KD Nolph, BF Prowant, ZJ Twardowski, DG Oreopoulos. Peritoneal Dialysis Bulletin, Toronto 1990; 6: 53–55
   Google Scholar
• Arfeen S, Goodship TH, Kirkwood A, Ward MK. The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution. Clin Nephrol. 1990; 33: 192–199
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986; 62: 249–257
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with CAPD. Clin Nephrol. 1992; 38: 271–276
   PubMed Web of Science ®Google Scholar
• Kimak E, Solski J. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, CAPD and post-transplant patients. Ren Fail. 2002; 24: 187–195
   PubMed Web of Science ®Google Scholar
• Heimburger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B. Increased plasma lipoprotein(a) in CAPD is related to peritoneal transport of proteins and glucose. Nephron. 1996; 72: 135–144
   PubMed Web of Science ®Google Scholar